Home Cart Sign in  
Chemical Structure| 298-46-4 Chemical Structure| 298-46-4

Structure of Carbamazepine
CAS No.: 298-46-4

Chemical Structure| 298-46-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Carbamazepine is a blocker of sodium channel with IC50 of 131 μM in rat brain synaptosomes. It is an anticonvulsant drug.

Synonyms: CBZ; NSC 169864; Carbamazepine, Tegretol, Epitol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Carbamazepine

CAS No. :298-46-4
Formula : C15H12N2O
M.W : 236.27
SMILES Code : O=C(N1C2=CC=CC=C2C=CC3=CC=CC=C31)N
Synonyms :
CBZ; NSC 169864; Carbamazepine, Tegretol, Epitol
MDL No. :MFCD00005073
InChI Key :FFGPTBGBLSHEPO-UHFFFAOYSA-N
Pubchem ID :2554

Safety of Carbamazepine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H373
Precautionary Statements:P501-P260-P270-P264-P314-P301+P312+P330

Isoform Comparison

Biological Activity

Target
  • Sodium Channel

    Sodium channel, IC50:131 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
C1R-HLA-B*15:02 transfectants 25 μg/mL 48 hours Co-culture experiments showed TCR immune response to carbamazepine Nat Commun. 2019 Aug 8;10(1):3569.
HeLa cells 20 μM 24 hours Reduced ER stress caused by N617K collagen X mutation, decreased intracellular mutant collagen X protein levels J Clin Invest. 2017 Oct 2;127(10):3861-3865.
RAW 264.7 cells 50 μM 24 hours Enhanced autophagic killing of intracellular mycobacteria EMBO Mol Med. 2015 Feb;7(2):127-39.
Primary human macrophages 50 μM 24 hours Enhanced autophagic killing of intracellular M. tuberculosis EMBO Mol Med. 2015 Feb;7(2):127-39.
HEK293T cells 8-64 μM 24 hours To assess the effects of carbamazepine on Wnt signaling, results showed that carbamazepine can partially suppress Wnt3a-induced luciferase activity J Med Chem. 2020 Mar 26;63(6):3252-3260.
Hippocampal neurons 100 µM 24 hours Induced autophagic flux and restored mitochondrial homeostasis Cell Rep. 2016 Oct 18;17(4):1053-1070.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
HLA-B*15:02 transgenic mice SCAR model Oral 328 mg/kg/day Daily administration for 4 weeks Induced multi-organ injuries and SCAR symptoms Nat Commun. 2019 Aug 8;10(1):3569.
Mice PRRT2-deficient mouse model Intraperitoneal injection 15 mg/kg Single dose Carbamazepine significantly alleviated paroxysmal dyskinesia phenotypes in PRRT2-deficient mice Cell Res. 2018 Jan;28(1):90-110
Mice MCDS mouse model Gavage 250 mg/kg body weight/day 1 to 3 weeks Reduced ER stress, improved chondrocyte differentiation, increased bone growth rates, reduced skeletal dysplasia J Clin Invest. 2017 Oct 2;127(10):3861-3865.
C57BL/6 mice Clostridioides difficile infection (CDI) model Oral gavage 50 mg/kg Every other day for 2 weeks To evaluate the effect of carbamazepine on CDI symptoms and lysosomal function. Results showed that carbamazepine alleviated TcdB-induced lysosomal dysfunction, inflammation, and histological damage. Autophagy. 2022 Sep;18(9):2050-2067.
Zebrafish PTZ-induced seizure model Immersion 50 μg/mL and 100 μg/mL 20 minutes To evaluate the anti-seizure effect of carbamazepine in the PTZ-induced zebrafish seizure model. Results showed that carbamazepine significantly inhibited seizures at doses of 50 μg/mL and 100 μg/mL. J Adv Res. 2024 Oct;64:249-262.
Mice Trigeminal neuralgia model Oral 60 mg/kg 12-hour interval Carbamazepine significantly decreased S1 synchronization and alleviated mechanical allodynia and facial grooming behavior J Clin Invest. 2023 Mar 1;133(5):e166408
Mice Infected with highly virulent MDR M. tuberculosis CSU87 Intraperitoneal injection 50 mg/kg Once daily for 30 days Reduced bacterial burden in lung and spleen, improved lung pathology and stimulated adaptive immunity EMBO Mol Med. 2015 Feb;7(2):127-39.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01581918 Chemotherapy-induced Nausea an... More >>d Vomiting Less << PHASE2 UNKNOWN - ABC Medical School, Santo Andr... More >>é, S?o Paulo, Brazil Less <<
NCT04371575 Trigeminal Neuralgia|Multiple ... More >>Sclerosis|Pain, Neuropathic Less << COMPLETED 2019-12-31 -
NCT00207428 Bronchial Asthma PHASE4 COMPLETED 2000-04-01 -
NCT00000191 Cocaine-Related Disorders PHASE2 COMPLETED 1994-02-01 University of Pennsylvania, Ph... More >>iladelphia, Pennsylvania, 19104 6178, United States Less <<
NCT00000242 Cocaine-Related Disorders|Subs... More >>tance-Related Disorders Less << PHASE2 COMPLETED 1997-01-25 Medical University of South Ca... More >>rolina, Charleston, South Carolina, 29425 742, United States Less <<
NCT00000217 Cocaine-Related Disorders|Subs... More >>tance-Related Disorders Less << PHASE2 COMPLETED - University of Kansas, Kansas C... More >>ity, Missouri, 64128, United States Less <<
NCT01089855 Neuropathic Pain PHASE4 COMPLETED - Novartis Investigational Site,... More >> Rabat, Morocco Less <<
NCT00000218 Cocaine-Related Disorders|Subs... More >>tance-Related Disorders Less << PHASE4 COMPLETED 2025-06-05 University of Kansas, Kansas C... More >>ity, Missouri, 64128, United States Less <<
NCT00153296 Bronchial Asthma PHASE4 COMPLETED 2025-04-05 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.23mL

0.85mL

0.42mL

21.16mL

4.23mL

2.12mL

42.32mL

8.46mL

4.23mL

References

 

Historical Records

Categories